Kornimate/medical-research-clean huggingface dataset:
fruquintinib combined with adebrelimab and high and low dose radiotherapy in the treatment of second-line and above failure mss metastatic colorectal cancer.

Conditions: MSS Metastatic Colorectal Cancer

Summary: the goal of this clinical trial is to learn about fruquintinib combined with adebrelimab and high and low dose radiotherapy in the treatment of second-line and above failure mss(microsatellite stability) metastatic colorectal cancer. the main question it aims to answer is: the efficacy and safety of fruquintinib combined with adebrelimab and high and low dose radiotherapy in the third line and beyond treatment of mss metastatic colorectal cancer. participants will receive the combination of fruquintinib and adebrelimab within 3 weeks after completion of high and low dose radiotherapy on metastases until disease progression or intolerable toxicity occurred.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old, gender not limited； 2. eastern cooperative oncology group (ecog) performance status (ps) score 0-1； 3. previously identified as mss type mcrc； 4. metastatic colorectal cancer (mcrc) with disease progression after receiving standard second-line treatment according to chinese society of clinical oncology ( csco) guidelines； 5. at least one measurable lesion (recist 1.1)； 6. be able to adhere to the protocol during the research period； 7. sign the informed consent form. exclusion criteria: 1. for individuals with a history of uncontrolled epilepsy, central nervous system disorders, or mental disorders, the clinical severity of which may hinder the signing of informed consent forms or affect the patient's adherence to oral medication, as determined by the researcher； 2. accompanied by other malignant tumors that have not been cured； 3. the baseline blood routine and biochemical indicators of the subject do not meet the following criteria: hemoglobin ≥ 90g/l; absolute neutrophil count (anc) ≥ 1.5 × 109/l; platelets ≥ 100 × 109/l; alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤ 2.5 times the normal upper limit; alkaline phosphatase (alp) ≤ 2.5 times the normal upper limit value; serum total bilirubin\<1.5 times the normal upper limit value; serum creatinine\<1 times the upper limit of normal; serum albumin ≥ 30g/l； 4. serious (i.e. active) heart disease in clinical practice, such as symptomatic coronary heart disease, congestive heart failure, or severe arrhythmia requiring medication intervention, or a history of myocardial infarction in the past 12 months； 5. irreversible coagulation dysfunction or concurrent active massive bleeding； 6. combination of active infections requiring antibiotic treatment； 7. individuals who are allergic to any research drug ingredients； 8. women with concurrent pregnancy or lactation； 9. organ transplantation requires immunosuppressive therapy and long-term hormone therapy； 10. patients with autoimmune diseases； 11. there is a history of drug treatment in previous plans。

Keywords: mss metastatic colorectal cancer fruquintinib adebrelimab high and low dose radiotherapy
pericapsular nerve group (peng) block combined with periarticular multimodal drug injection (pmdi) versus isolated pmdi for pain management after total hip arthroplasty: a randomized controlled trial

Conditions: Total Hip Arthroplasty, Postoperative Pain

Summary: adequate pain control after total hip arthroplasty is crucial for early ambulation and patient satisfaction. however, there is no consensus about optimal pain control after post operation. in general, the periarticular multimodal durg injection block has been done for pain control in primary total hip arthroplasty. the pericapsular nerve group (peng) block has been recently introduced a new technique for blockade of the articular branches of the femoral, obturator and accessory obturator nerves. peng block is possible to provide sufficient analgesia and preserve lower limb muscle strength. the investigators will compare peng and pmdi block with isolated pmdi block in patients undergoing total hip arthroplasty.


Eligibility criteria:
inclusion criteria: 1. patients aged 19 years old or older, with american society of anesthesiologists physical status 1-3, and scheduled for elective unilateral total hip arthroplasty exclusion criteria: 1. allergy or intolerance to any of the drugs used in the study 2. hepatic or renal insufficiency 3. opioid dependency 4. coagulopathy 5. pre-existing neurologic or anatomic deficits in the lower extremities 6. severe psychiatric illness
cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention

Conditions: Ovarian Hyperstimulation

Summary: giving oral cabergoline or calcium infusion in women at high risk for developing ovarian hyperstimulation syndrome in context of assisted reproductive technologies aiming in its prevention

women undergoing in vitro fertilization or intracytoplasmic sperm injection whom were at high risk for developing ovarian hyperstimuation syndrome were received either oral cabergoline.5mg tablets for 7days starting on ovum pick up day and continued for 7days or received 10ml of 10%calcium gluconate in 200ml normal saline on ovum pick up day and continued for 4days

Eligibility criteria:
inclusion criteria: * women undergoing assisted reproductive technologies whom at high risk for developing ovarian hyperstimulation syndrome as with high basal antimullerian hormone ,excess antral follicular count ,high seum estradiol on day of humian choronic gonadotrophin exclusion criteria:women with other endocrinopathy as congenital adrenal hyperplasia , hyperprolactinemia,diabetes -

Keywords: calcium infusion cabergoline
effect of t4-t3 combination therapy versus t4 monotherapy in patients with hypothyroidism

Conditions: Quality of Life; Depression

Summary: to compare the effect of t4-t3 combination therapy versus t4 monotherapy in patients with autoimmune hypothyroidism, on stable t4-substitution therapy

double blind randomized cross-over study.

Eligibility criteria:
inclusion criteria: * hypothyroidism, s-tsh\> 20 at diagnosis,anti-tpo \>300 normal tsh (0,4-4,0) for 6 months. exclusion criteria: * \<18 år * \>75 år * pregnant women * thyroid cancer * t3 treatment * post-partum thyroiditis

Keywords: hypothyroidism, quality og life, depression
a study to determine the efficacy and safety of tividenofusp alfa (dnl310) vs idursulfase in pediatric and young adult participants with neuronopathic (nmps ii) or non-neuronopathic mucopolysaccharidosis type ii (nnmps ii)

Conditions: Mucopolysaccharidosis II

Summary: this is a phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (dnl310), an investigational central nervous system (cns)-penetrant enzyme-replacement therapy (ert) for mucopolysaccharidosis type ii (mps ii). participants may also qualify to enter an open-label treatment phase with dnl310 or idursulfase based on pre-specified criteria.


Eligibility criteria:
key inclusion criteria: * participants aged ≥2 to \<6 years (cohort a) or ≥6 to \<26 years (cohort b) * confirmed diagnosis of mps ii (for cohort a, nmps ii; for cohort b, nnmps ii) * have no history of treatment with enzyme replacement therapy (ert) or not have received continuous ert for 4 months prior to screening or be on maintenance ert and have tolerated idursulfase for a minimum of 4 months prior to screening key exclusion criteria: * have a documented mutation of other genes or genetic diagnosis accounting for developmental delay * previously received an iduronate 2-sulfatase (ids) gene therapy or stem cell therapy * received any cns-targeted mps ert within 6 months prior to screening * have a contraindication for lumbar punctures and/or magnetic resonance imaging (mri) * participated in any other investigational drug study or used an investigational drug within 60 days prior to screening or intend to receive another investigational drug during the study

Keywords: hunter syndrome mps ii nmps ii nnmps ii
cilostazol-simvastatin drug interaction study

Conditions: Dyslipidemias; Peripheral Artery Disease

Summary: this is a randomized, open-label, single \& multiple-dose, parallel study to investigate the effect of cilostazol on the disposition of simvastatin \& pravastatin in healthy male volunteers

eligibility for participation of this study will be determined from demographic information, medical history, physical examination, electrocardiogram (ecg) and clinical laboratory tests within 4 weeks before study drug administration. subjects suitable for this study will be admitted to the clinical trial center of ajou university medical center on the day before dosing (day -1). on day 1, subjects will be dosed simvastatin 40 mg or pravastatin 20 mg. pharmacokinetic samplings and blood pressure/pulse rate measurement will be done upto 24 hours after dosing. from day 2 \~ 7, subjects will be dosed cilostazol 100 mg twice a day. on day 8, subjects will be dosed simvastatin 40 mg or pravastatin 20 mg with cilostazol 100 mg twice a day. pharmacokinetic samplings and blood pressure/pulse rate measurement will be done upto 24 hours after dosing.

Eligibility criteria:
inclusion criteria: * healthy male subjects aged 20 - 45 years * with in 20% of ideal body weight, {ideal body weight=\[height(cm)-100\]\*0.9} * agreement with written informed consent exclusion criteria: * clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal disease or mental disorder (past history or present) * inadequate result of laboratory test (especially, ast/alt \> 1.25 x unl, total bilirubin \> 1.5 x unl) * positive reaction in the hbs ag, anti-hcv ab, anti-hiv ab, vdrl test * taking otc(over the counter)medicine including oriental medicine within 7 days * clinically significant allergic disease (except for mild allergic rhinitis and dermatitis seems to be not need for medication) * subject with known for hypersensitivity reaction to cilostazol, simvastatin or pravastatin * previous whole blood donation within 60 days or component blood donation within 30 days * previous participation of other trial within 90 days * continued taking caffeine (caffeine \> 5 cup/day), drinking (alcohol \> 30 g/day) and severe heavy smoker (cigarette \> 1/2 pack per day) * an impossible one who participates in clinical trial by investigator's decision including for reason of laboratory test result

Keywords: drug-drug interaction pharmacokinetics
the effects of surgery performed at different times of the day on inflammation and recovery

Conditions: Inflammatory Response

Summary: to evaluate the inflammatory response of participants who will undergo unilateral inguinal hernia surgery at two different times of the day (08.00-12.00 during the day and 18.00-22.00 at night). the main question it aims to answer is; is the inflammation response higher in participants who undergo surgery later in the day? serum inflammatory parameters will be measured in both groups at the preoperative 1st hour and the postoperative 24th hour.

participants who would undergo unilateral inguinal herniography surgery at different times during the day were determined into two groups: day (08.00-12.00) and night (18.00-22.00). the athens insomnia scale (ais) will be asked verbally on the first preoperative day to determine the participants' preoperative circadian rhythm adaptation and sleep status. serum inflammatory parameters of both participant groups will be measured and recorded at the preoperative 1st hour and the postoperative 24th hour. a laryngeal mask will be applied to the participants after induction with 2-3 mg/kg propofol and 1mg/kg fentanyl, as in routine anesthesia practice. anesthesia maintenance will be provided with sevoflurane and 0.05-0.2 mcg/kg/min remifentanil infusion. participants' age, gender, weight, height, bmi (body mass index), comorbidities, medications used, surgeries, asa (american society of anesthesiologists) scoring, preoperative ais (athens insomnia scale) score, and preoperative laboratory data will be recorded. at the same time, participants' postoperative hospital stay, resting and moving nrs (numeric rating scale) scores at the 24th postoperative hour, and recovery quality (qor-15 score) from anesthesia will be recorded.

Eligibility criteria:
inclusion criteria: * asa (american society of anesthesiologists) 1-2 adult participants between the ages of 18-70 who will undergo unilateral inguinal herniorrhaphy surgery at the republic of turkey ministry of health ankara city hospital. exclusion criteria: * do not want to participate in the study * younger than 18 or older than 70 * scores 6 and above on the preoperative athens insomnia scale. * asa (american society of anesthesiologists) scores of 3 or greater than 3 * have contraindications to the use of anesthetic drugs * bmi\>30 kg/m\^2 * have bilateral herniorrhaphy surgery * complicated inguinal hernia (incarcerated, strangulated...) * pregnancy * emergency surgeries * laparoscopic surgeries * develop an unexpected intraoperative surgical complication

Keywords: circadian rhythm postoperati̇ve recovery
tai chi versus conventional exercise to improve cognitive performance in older adults with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: this randomized controlled trial aims to evaluate the effectiveness of tai chi and conventional exercise on improving cognitive function in older adults with mild cognitive impairment (mci). participants will be randomized into three six-month programmes, namely health education group, tai chi group and conventional exercise group. assessments will be conducted at baseline, after the 26-week interventions, and 26-week after the competition of the intervention.


Eligibility criteria:
inclusion criteria: * chinese older adults aged equal or larger than 50 years * ethnic chinese * mci under criteria of mayo clinic, including the following i. people with subjective complaint about a decline in cognitive function. ii. total score in the montreal cognitive assessment is equal or below the 7th percentile of the age- and education- corrected normative data of hong kong. iii. the decline in cognitive function does not impair daily functioning, as revealed by getting ≥2 marks in every item on the chinese lawton instrumental activities of daily living 4-point scale). exclusion criteria: * medical history of major chronic diseases such as cancer, stroke, cerebro- and cardio-vascular diseases, and renal disease * uncontrolled diabetes * diagnosed with dementia or using anti-dementia medication * diagnosed with psychiatric diseases or using psychiatric medication * with diseases or on medications known to severely affect cognitive performance * somatic condition (e.g., limb lost) that prevent participation in exercise * impaired mobility by chronic diseases (e.g., neurological, musculoskeletal and autoimmune diseases) * incapable to perform physical exercise * regular exercise habit (\>3 times 60-min tai chi or moderate-intensity conventional exercise weekly) in the past 3 months
citrulline supplementation on vascular responsiveness and function in postmenopausal women

Conditions: Menopause

Summary: the objective of this project is to provide evidence that l-citrulline (l-cit) supplementation can improve vascular function at rest and in response to exercise in postmenopausal women.

l-cit is a non-essential amino acid that is a precursor to l-arginine, the substrate used to produce an important vasodilatory molecule called nitric oxide. the purpose of this study is to identify the effects of 6 grams of l-cit for 4 weeks on vascular function (endothelial function, blood flow, muscle oxygenation, and blood pressure) at rest and in response to different stressors (cold pressor test, isometric and dynamic exercise).

Eligibility criteria:
inclusion criteria: * postmenopausal (absence of menstruation \> 1 year) between the ages of 50 - 79 years. * sedentary ( \< 120 minutes of exercise/week) * resting systolic blood pressure \< 150 mmhg and diastolic blood pressure \< 90 mmhg * not participating as a subject in another study for at least 2 months prior to the study and for the duration of the study * willingness to abstain from food supplements 1 month prior to the start of the study and throughout the duration of the study exclusion criteria: * body mass index ≥ 40 * currently taking more than one vasoactive drug for blood pressure control * cardiometabolic diseases or other chronic diseases * taking hormone replacement therapy 3 months prior to the study * current or prior use of tobacco products * more than a moderate intake of alcohol * use of medications and/or supplements that may affect outcome variables * musculoskeletal disorders that will prevent exercise performance

Keywords: endothelial function blood pressure blood flow
custodiol-n solution compared with custodiol solution in organ transplantation (kidney, liver and pancreas)

Conditions: Kidney Failure; Liver Failure, Chronic; Kidney-Pancreas Failure

Summary: synopsis title of study a prospective, randomized, single blind multicentre phase iii study on organ preservation with custodiol-n compared with custodiol solution in organ transplantation (kidney, liver and pancreas) protocol number: cl-n-klp-tx-iii/07-at/17 trial design the study design is a prospective, randomized, single blind, multicentre, phase iii comparison study of organ perfusion intended to demonstrate non-inferiority of custodiol-n against custodiol in organ transplantation of kidney, combined kidney-pancreas and liver. intended duration of study the overall duration for the trial is expected to be approximately 30 months. the du-ration of the trial for each subject is expected to be 3 months (transplantation and a follow-up period of 90 days). purpose of the study the objective of this investigation is to demonstrate non-inferiority of graft preservation with custodiol-n compared to custodiol with respect to both graft function and injury after transplantation of kidney, liver or combined kidney-pancreas. patient selection the study population will be selected from patients who will undergo kidney, liver or combined kidney-pancreas transplantation. patients of each gender will be included in the study. planned number of patients (recipients) in total n=362 including: kidney 242 (including approx. 30 combined kidney-pancreas) liver 120


Eligibility criteria:
inclusion criteria: * all organs (kidney, combined kidney - pancreas and liver) donor criteria for all patients undergoing deceased donation: - deceased adult (≥18 years) donors fulfilling the criteria for organ donation for all patients undergoing living kidney donation: - adult (≥18 years) living kidney donors fulfilling the criteria for organ donation patient (recipient) criteria * recipients awaiting their transplant * recipients ≥18 years * recipients' signed informed consent before the transplantation kidney / combined kidney - pancreas recipients * n/a liver recipient * full organ transplantation exclusion criteria: * all organs (kidney, combined kidney - pancreas and liver) donor criteria (not applicable for living kidney donors) * - donors whose organs are all allocated out of retrieving study center * general refusal of organ donation * donation after cardiac death (dcd) patient (recipient) criteria * pregnant or lactating patients * recipients participating in any interventional study (e.g. another study involving compound/interventions aimed at the reduction of preservation and / or ischemia / reperfusion injury) * all combined allocations other than pancreas and kidney kidney / combined kidney -pancreas recipient * double kidney transplantation * pancreas retransplantation * machine perfusion according to the kdigo-guidelines (2009) all patients with pra \>0% are only included in the living donation setting. liver recipient * retransplantation * machine perfusion
intranasal insulin for prevention of type 1 diabetes

Conditions: Type 1 Diabetes

Summary: children born in turku, oulu and tampere university cities in finland are screened at birth for hla alleles that carry increased risk to or protection from development of type 1 diabetes. children carrying increased risk are followed at 3-12-month intervals for development of diabetes-associated autoantibodies. children having at least two types of autoantibodies (of the four measured) in at least two consecutively drawn samples are randomized to receive daily intranasal insulin or placebo in a double-blinded 1:1 trial. hypothesis is that intranasal insulin delays or prevents development of clinical type 1 diabetes. the primary outcome measure is development of clinical diabetes.

children born in turku, oulu and tampere university cities in finland are screened at birth for the hla-dqb1 and dqa1 alleles that carry increased risk to or protection from development of type 1 diabetes. children carrying increased risk are followed at 3-month intervals until 2 years of age and then at 6-12-month intervals until,15 years of age for development of diabetes-associated autoantibodies (autoantibodies against islet cells, insulin, glutamic acid decarboxylase and ia-2 protein). children having at least two types of autoantibodies of the four measured in at least two consecutively drawn samples are randomized to receive daily intranasal insulin or placebo in a double-blinded 1:1 trial. hypothesis is that intranasal insulin delays or prevents development of clinical type 1 diabetes. the primary outcome measure is development of clinical diabetes, but serum concentrations of autoantibodies, responses to intravenous glucose tolerance test and possible side effects of therapy are also closely monitored.

Eligibility criteria:
inclusion criteria: * children carrying hla-conferred genetic risk for developing type 1 diabetes * have had at least two types of autoantibodies of ica, iaa, gada and ia-2a in at least two consecutive blood samples drawn at least 3 months apart * age at least one year exclusion criteria: * severe other disease * age above 15 years

Keywords: diabetes juvenile diabetes insulin deficiency
enhancing prospective thinking in early recovery (home)

Conditions: Alcohol Use Disorder

Summary: the goal of this clinical trial is to use a novel virtual reality intervention to test for efficacy in reducing alcohol use and increasing abstinence, with concomitant increases in future self-identification, future time perspective, and delay-of-reward, in early recovering alcohol use disorder (aud) persons. the main question\[s\] this trial aims to answer are: will the virtual reality (vr) intervention decrease the number of stimulant use days? will the vr intervention produce longer abstinence periods during follow-up visits? will the vr intervention increase alcohol abstinence rates? will the vr intervention increase future self-identification? will the vr intervention increase self-reported future time perspective? will the vr intervention increase preference for delayed rewards in a laboratory delay discounting task on the study day? will the vr intervention produce gains in the behavioral effects of future self-identification, future time perspective, and delayed rewards at the 30-day and 6-month follow-ups? researchers will compare the experimental and control groups to see if there are differences in the results for the questions outlined above.


Eligibility criteria:
inclusion criteria: * abstinence between ≥14 days and ≤1 year * verbal endorsement of commitment to recovery * outpatient * psychotropic drugs for sud-comorbidity * drug/alcohol abstinence ≥ 24 hours at the time of the study day visit * english comprehension exclusion criteria: * unstable medical disorders * habitual drug use * mu-opioid drugs * smell/taste disorders * unstable psychiatric conditions * extravagant/elaborate face tattoos